| Autor: |
Ben Bnina, Amène, Ben Dhia, Refka, Gnaba, Sahar, Annabi, Alaa, Chouchane, Syrine, Naija, Walid, Said, Houyem, Oueslati, Abderraouf, Bouatay, Amina |
| Předmět: |
|
| Zdroj: |
Pan African Medical Journal; May-Aug2022, Vol. 42, p1-10, 10p |
| Abstrakt: |
Introduction: thrombotic events are the most severe complications of the coronavirus disease 2019 (COVID-19). It is known that antiphospholipid antibodies (APL) could be involved in thrombosis mechanism. Thus, APL profiles were studied particularly in patients with severe and critical COVID-19, and their clinical impact. Methods: a retrospective study of 54 COVID-19 hospitalized patients (34 in intensive care unit (ICU) and 20 in non-ICU) was conducted. These COVID-19 patients were tested for the presence of LAC (lupus anticoagulant) using the ACLTOP750®, anti-cardiolipine (ACL) and anti-ß2glycoprotéine I (anti-ß2GPI) IgG/IgM/IgA by enzyme-linked immunosorbent assay (ELISA). IgA isotype was tested in only 25 patients. Results: antiphospholipid antibodies were present in 74.1% of tested patients. LAC positivity was the highest (60.8%) among all patients, followed by IgM aCL (18.5%) and IgM anti-ß2GPI (14.8%). Besides, LAC and anti-ß2GPI IgA were the most predominant APL regarding the 25 patients tested for IgA isotype (52% and 24% respectively). Nine patients had thrombotic events, among them 6 were positive in APL and 5 were positive in LAC. However, there was any significant association between APL positivity or titers and thrombosis. There was also no significant difference between the two COVID-19 groups regarding APL profiles. Conclusion: given the relatively high frequency of APL and especially LAC, and given the multitude of thrombotic risk factors in these severely and critically ill COVID-19 patients, a prophylactic anticoagulation remains essential. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
